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Thirty chemicals or substances currently undergoing long-term carcinogenicity bioassays in
rodents have been used in a project to further evaluate methods and information that may have
the capability of predicting potential carcinogens. In our predictions the principal information used
includes structural alerts and in vitro test results for Salmonella mutagenicity, relative subchronic
toxicity, and the sites and types of pathology found in subchronic (90-day) studies. This group of
chemicals differs significantly from those used previously to evaluate predictive methods in that
23 of 30 are defined as nonmutagenic by conventional criteria. The goal of this predictive effort is
to identify categorically the chemicals that have the capacity to induce cancers in both rats and
mice (trans-species carcinogens) and those that are not carcinogenic in either rats or mice.
Chemicals that show properties that may be associated with tumor induction in either species,
i.e., species-specific cancers, are categorized as being of "uncertain predictability." This category
includes chemicals believed to have limited carcinogenic potential that is manifested principally as
a consequence of the genetic background of the test strain of inbred rodent. Environ Health
Perspect 104(Suppl 5):1095-1100 (1996)
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Introduction
An effort was initiated in 1990 to utilize
ongoing rodent carcinogenicity bioassays
to test the capability ofusing both chemical
and biological parameters to predict poten-
tial carcinogens (1). It was anticipated that
this would be an iterative process in which
insights and knowledge gained in the first
phase would be utilized to improve subse-
quent prediction capability. In the first
phase ofthe project 44 chemicals undergo-
ing rodent bioassays by the U.S. National
Toxicology Program (NTP) were utilized
as the target and our predictions were
published to encourage the application of
predictive methodologies by other investi-
gators. Seven other prediction efforts for
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these chemicals were also published (2).
We believe that this initial effort success-
fully demonstrated that the parameters of
chemical structure, genotoxicity, and
rodent toxicity can be used to predict
potential carcinogenicity (3). Further,
among the various predictive methodolo-
gies reported, the highest degree ofconcor-
dance was achieved for chemicals showing
the clearest carcinogenic and noncarcino-
genic effects. The most problematic chemi-
cals were those showing either sex- and
species-specific or weak carcinogenic effects
and those producing equivocal results.
The same biological and chemical para-
meters cited above and used in our previ-
ous effort (1) have been used in this second
predictive exercise that involves 30 chemi-
cals currently undergoing rodent bioassay.
The principal difference in our approach to
predicting the activity ofthis second group
of chemicals is that we are demarcating
more precisely the carcinogenic activity
that we are attempting to predict. Extensive
analysis of the results ofbioassays over the
past few years has provided insights into
the nature of the carcinogenic responses
induced in F344 rats and B6C3F1 mice,
the two rodent strain/species (4,5) pre-
dominantly used in the NTP 2-year bioas-
say. We have proposed a stratification of
bioassay results that is indicative ofthe rel-
ative potency ofcarcinogens (6). The cate-
gory that reflects the greatest carcinogenic
potential is that of the trans-species car-
cinogens that induce tumors at one or
more sites in both rats and mice; a particu-
lar subcategory is represented by those that
induced tumors at the same sites or ofthe
same histogenic type in both species. The
least carcinogenic potential is represented
by the chemicals that induce tumors at
only one site in only one of the four sex/
species groups. This stratification is based
on the recognition that inbred rodents pos-
sess an allelic distribution that is uncharac-
teristic ofthe type and frequency found in
feral or outbred populations. That is, vari-
ous alleles ofpolymorphic genes are repre-
sented in outbred populations with variable
frequency (7). As a consequence ofselected
or random inbreeding, the rodent lines lose
many ofthe polymorphic alleles and subse-
quently possess a more limited number of
specific alleles, which are uniformly distrib-
uted in the inbred animals. Two conse-
quences of this allelic enrichment are that
the various inbred strains demonstrate
specific patterns of spontaneous tumors
and that they can exhibit strain-specific
responses to chemicals (6-8).
Both of these consequences may be in
part responsible for much of the contro-
versy surrounding the interpretation of
bioassay results and the appropriateness of
their extrapolation for human risk. For
example, chemicals that are identified as
carcinogens based solely on increases in
tumors that occur spontaneously at a high
frequency (e.g., >10%), may only modu-
late the expression of the gene(s) that
determine the disease. Since these tumors
are a genetic disease of the specific rodent
strain, the chemical effects may be of little
consequence in other species or even other
strains of the same species. The action of
the trans-species carcinogens are indepen-
dent ofstrain-specific influences and may
therefore pose the greatest risk in other
species, whereas the risk of the strain-
specific carcinogens may affect only certain
individuals in an outbred population.
The implications ofthe stratification of
carcinogens for the prediction of carcino-
genic potential is that any prediction
schema must be risk-averse. That is, it must
Environmental Health Perspectives * Vol 104, Supplement 5 * October 1996
.M
1 095TENNANTAND SPALDING
be possible to reliably predict trans-species
carcinogens. Conversely, since the genetic
and biochemical basis of strain-specific
effects induced by carcinogens is not gener-
ally known, it is unlikely that they can be
reliably predicted and this category ofcar-
cinogens should not be a principal basis for
judging how effective prediction methods
may be. A corollary to this is that the
methods should also be able to reliably pre-
dict which chemicals are unlikely to induce
tumors in either bioassay species.
Results
As in the previous exercise (1), our predic-
tions reflect a weight-of-evidence call based
on structural alerts and Salmonella muta-
genicity data, the subchronic bioassay toxi-
city data, and the maximum tolerated dose
(MTD) levels set for the two-year bioassay.
The goal of our effort to predict the car-
cinogens among the 30 current chemicals
is to identify all of those chemicals with
trans-species carcinogenic potential and
those that are noncarcinogens. In our view
the data available for predicting the other
chemicals cannot be reliably used to infer
which may induce strain-specific tumori-
genic effects; therefore all of our predic-
tions of carcinogenicity reflect a primary
concern for trans-species effects. Some data
may be an alert for potential strain-specific
effects, such as subchronic target-organ
toxicity for tissues in which spontaneous
tumors are frequent; but we have not been
able to identify any reliable parameters.
Likewise, we have not identified parame-
ters of toxicity for chemicals that may
induce single site/single sex/species tumors
that are not associated with spontaneous
tumors. This uncertainty will result in such
chemicals being identified as probable
noncarcinogens.
Some ofthe aspects ofsubchronic toxi-
city that have been identified in Table 1
have been associated with the observed
strain- or species-specific responses seen in
bioassays of other chemicals. They have
been highlighted in the table as a possible
alert to such specific carcinogenic effects
even though they have no reliable predic-
tive value. For example, hyalinelike
droplets are often deposited in rat kidney
tubular epithelium as a consequence of
chronic toxicity and also have been associ-
ated with "2p-globulin related kidney
tumors in male rats (9-11).
In this exercise we have identified 3 of
the 30 chemicals as probable (trans-species)
carcinogens, ofwhich gallium arsenide is a
nonmutagen. Ten of the 30 are predicted
to be noncarcinogens. We have abstained
from predicting for 2 chemicals because
the outcome ofthe bioassay is known. This
group of 30 chemicals poses a particular
challenge, compared to the first exercise
(1), since 23 ofthem are not mutagenic in
the Salmonella assay. Though a few para-
meters related to the carcinogenicity of
nonmutagens are known (e.g., peroxisome
proliferation (11-15) and a2p-globulin
hyaline droplet induced nephropathy, etc.
(9-11) none are clearly represented among
this group. This is particularly important
since many of the chemicals that induce
strain-specific carcinogenic effects are not
mutagens. Consequently, 15 ofthe chemi-
cals have been classified as being of"uncer-
tain predictability" to indicate that it is
possible that strain- or species-specific neo-
plasia could be a consequence ofchronic
exposure. The above caveats may seem like
a rationale for anticipated missed predic-
tions. That is not the case because we are
categorical in our efforts to predict trans-
species carcinogens and noncarcinogens
and the success or failure ofour predictions
should bejudged critically on that basis.
Discussion
In evaluating the potential carcinogenicity
of these chemicals we have again placed
primary emphasis on structural alerts,
mutagenicity for Salmonella, relative toxic-
ity (reflected in the maximum dose tested)
and the sites and type of subchronic
pathology. These properties are described
in Table 1, together with brief comments
or explanations ofthe basis for our predic-
tion. The large number of chemicals
deduced to be of uncertain predictability
reflects a different distribution ofchemicals
than those for which predictions were
offered in 1990 (1). It is not anticipated
that any ofthis group of 15 chemicals will
induce trans-species carcinogenesis, but some
will be associated with equivocal effects or
the induction of site or species-specific
carcinogenesis. A majority are anticipated
to be noncarcinogens but some aspect of
the subchronic toxicologic evaluation of
the chemicals raises the possibility that they
could be associated with site- or species-
specific neoplastic effects.
It is unlikely that species- and strain-
specific carcinogenicity will be predictable
until the genetic basis of these occurrences
is better understood. The rapid evolution
in mouse genetics, in the utilization of
transgenic and knockout technology to
study chemical-gene interactions, and in
sequencing the mouse genome to improve
the identification and cloning of genes,
holds the promise that specific genes and
mechanisms underlying carcinogen suscep-
tibility can be understood. We believe that
at least two discrete mechanisms are
involved: interaction of some chemicals
with genes or gene products that modify
the spontaneous tumor incidence ofinbred
rodents, and interactions with genes that
influence tissue-specific susceptibility not
associated with spontaneous tumor sites.
These are potentially important issues in
utilizing rodent bioassay for protecting
public health and the environment. The
species- or strain-specific carcinogens are
unlikely to pose a public health problem
that is as important as that ascribed to
trans-species carcinogens. However, the
genes that influence or govern species/
strain specificity may be useful in identify-
ing susceptible individual humans. To
know if this is the case, it is necessary to
clone such rodent susceptibility genes to
determine if humans possess structural
analogs. However, since cancers are the
consequence ofmultiple genetic effects, the
predominant influence ofthe susceptibility
genes could be principally the consequence
ofextensive inbreeding.
We have proposed recently that specific
transgenic mouse lines can be utilized in
short-term carcinogenesis bioassays (8).
The results available thus far suggest that
the transgenic bioassays offer advantages
not only in time and cost savings and a
reduction in the number ofanimals needed
for bioassays, but that they also minimize
species-/strain-specific influences.
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Table 1. Predictions of carcinogenicity and noncarcinogenicity for 28 chemicals undergoing the bioassay bythe National Toxicology Program.a
Chemical name Structural alertb Maximum dose tested
Route of administration Salb in chronic bioassayc Subchronic histopathologyd
CAS no. (-/+ S9) Rats Mice Major target organs Comments and basis for prediction
Probable carcinogen: trans-species effe
Cobalt sulfate heptahydrate S
Inhalation +
10026-24-1
D&C Yellow No. 11e
Feed
8003-22-3
Gallium arsenide S
Inhalation
1303-00-0
Probable noncarcinogen
Cinnamaldehyde
Feed, microencapsulation
104-55-2
Citral
Feed, microencapsulation
5392-40-5
Codeinee
Feed
76-57-3
Ethylbenzene
Inhalation
100-41-4
Ethylene glycol monobutyl ether
Inhalation
111-76-2
Isobutene
Inhalation
115-11-7
3 mg/m3 3 mg/m3
0.50% NA NA
1.0 mg/m3 1.0 mg/m3
SA- Subchronic doses;
0, 1.25, 2.5, 5.0, 10%
SA- 2.5% 2.5%
SA- 0.16% 0.13%
SA- 750 ppm 750 ppm
SA- 125 ppm 250 ppm
SA+ 8000 ppm 8000 ppm
Lungs and lymph nodes,
both sex/species
Kidney, MR,
liver, MR, FR
Lungs and larynx,
both sex/species
Subchronic toxicity not
reported out
Forestomach, in both
sex/species;
bone marrow, MR, FR;
ovary, FM
No histopathologic lesions
found in exposed rats or mice
in 13-week subchronic study
Lung, MR, FR; no
histopathologic lesions were
found in mice
Forestomach, liver, and spleen
in both sex/species; bone
marrow, MR, FR; kidney,
MM, FM
Nasal cavity, MR, FR:
no histopathologic lesions
in mice
Carcinogen; mutagen: chronic inflammation in
lungs, bronchiolar epithelium regeneration; a
NOEL in the lungs of rats or mice was not found.
Carcinogen; mutagen: hyalinelike droplets in
MR kidney; absolute liverwt increase at every
dose; periportal degeneration at two highest
subchronic doses; these same doses selected
for chronic study.
Carcinogen; nonmutagen: chronic inflammation
in lungs; inorganic arsenic is a known
carcinogen in humans and an enhancer of
induced tumors in rats and mice; a NOEL was
not reached in the subchronic rat study.
Unlikely carcinogen; nonmutagen: if high dose
in the chronic study exceeds 2.5% in the diet,
then tumors at a sex/species specific target
organ site could occur.
Unlikely carcinogen; nonmutagen: hyperplasia
and hyperkeratosis of the forestomach epithe-
lium in rats and mice, probably compound
related; bone marrow atrophy and hemorrhage
in rats; atrophy of ovarian corpus luteum in
FM.Toxic lesions occurred at highest subchronic
dose, which is 4x highest chronic study dose.
(low, low risk; chronic irritation in the fore-
stomach by a nonmutagen does not easily result
in tumors).
Unlikelycarcinogen; nonmutagen: the absence of
any histopathologic lesions observed in the 13-
weeksubchronic study suggests that codeine will
prove to be a noncarcinogen in the 2-year chronic
study; rats exhibited poorweight gain in the
subchronic study because of lowered food intake.
Unlikely carcinogen; nonmutagen: lung
was the onlytarget organ in exposed rats, with
alveolarfocal accumulations of inflammatory
cells; these lesions were accompanied by
lymphoid hyperplasia ofthe bronchial and
mediastinal lymph nodes; the rat lung is a
possible target for neoplasia.Lack of any sub-
chronic lesions in mice suggests an absence of
any neoplastic effects in the chronic study.
Unlikely carcinogen; nonmutagen: chronic
epithelial hyperplasia of the forestomach in rats
and mice induced by a nonmutagen could result
in a low incidence offorestomach tumors; a
NOEL was NOT reached for FM; a NOEL for
hematologic effects in FR was NOT reached;
most ofthe target organ toxicity in both
sex/species occurred at highest subchronic
(500 pm) dose; a sex/species specific target
organ tumor response cannot be ruled out.
Unlikelycarcinogen; nonmutagen: minimal
hypertrophy ofgoblet cells lining the naso-
pharyngeal duct in most caudal nasal sections
occurred at all doses; no NOEL observed in rats;
1,3-butadiene and chloroprene, analogs of
isoprene, are carcinogens in rats and mice (NTP);
high dose of isobutene in the chronic study is
the same as the high subchronic dose; possible
nasal passage carcinogen in rats.
(continued)
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Table 1. (Continued)
Chemical name Structural alertb Maximum dose tested
Route of administration Salb in chronic bioassayc Subchronic histopathologyd
CAS no (-/+ S9) Rats Mice Majortarget organs Comments and basis for prediction
Molybdenum trioxidee
Inhalation
1313-27-5
Nitromethane
Inhalation
75-52-5
Scopolamine hydrobromide
trihydratee
Gavage
6533-68-2
Xylenesulfonic acid sodium salte
Skin paint
133-72-7
SA-NA
_I_
100 mg/m3 100 mg/m3
SA- 375 ppm 750 ppm
SA-
SI-
SA-
_I_-
No histopathologic lesions
observed in rats or mice
Nasal cavity, both sex/species;
bone marrow, MR; spleen,
MM, FM
25 mg/kg 25 mg/kg No histopathologic lesions
noted in rats or mice in
subchronic study
240 mg/kg 727 mg/kg
Uncertain predictability: possible sex-, species-, or strain-specific target organ sites
Anthraquinone SA- 0.18% 0.75%
Feed +/+
84-65-1
t-Butylhydroquinonee
Feed
1948-33-0
1-Chloro-2-propanol
Water
127-00-4
Diethanolamine
Skin paint
11-42-2
1,2 Dihydro-2,2,4-trimethyl-
quinolinee
Skin paint
147-47-7
Emodin
Feed
518-82-1
SA-
SA-
0.50% 0.50%
0.065% 0.10%
SA- 64 mg/kg MR
32 mg/kg FR
160 mg/kg MM, FM
SA- 100 mg/kg 10 mg/kg
SA- 0.125% 0.06%
Skin in both sex/species
Liver, both sex/species;
thyroid, MR; kidney, MR,
FR; bladder, MM, FM
Nasal lesions, both sex/species;
kidney, spleen, MR, FR; skin and
forestomach, MM, FM
Pancreas, both sex/species;
liver, MR
Skin and kidney in MR, FR;
skin and liver in MM, FM
Skin, both sex/species;
liver, MR, MM, and FM
Kidney, both sex/species
Unlikely carcinogen; nonmutagen: no
treatment-related gross or histopathology
noted, butthis was an early(1984) pathology
work group report; top dose in the subchronic
study was chosen as the top dose in the chronic
study; low, low risk.
Unlikely carcinogen; nonmutagen: olfactory epi-
thelial degeneration occurred in both sex/species
at subchronic doses chosen for the chronic
study; analogs, tetranitromethane (NTP) and
2-nitropropane are carcinogens in inhalation
studies; rats likely are more at risk than mice.
Unlikely carcinogen; nonmutagen: high dose
in chronic study setjust above lowest dose
in subchronic study because of severe reduction
in secretions at higher doses; top dose is
well below any expected chronic pathology.
Unlikelycarcinogen; nonmutagen: treatment-
related epidermal hyperplasia not considered
to lead to neoplasia; sulfonic acid group is
easily detoxified via conjugation and excreted.
Possible carcinogen; mutagen: liver
hypertrophy and inflammation at all doses in
rats and highest doses in mice; kidney
nephropathy in MR; hyalinelike droplets in
kidneys, MR and FR (thought to be parent
compound); urinary bladder effects at all doses
in mice. An analog, 2-aminoanthraquinone, is a
liver carcinogen in MR, MM, and FM;low to
moderate risk.
Unlikely carcinogen; nonmutagen: chronic
hyperplasia of nasal respiratory epithelium
in rats could lead to neoplasia; epidermal
hyperplasia ofthe skin and epithelial
hyperplasia ofthe forestomach in mice are
unlikely to lead to neoplasia, though a
spontaneous mutation in the cellular Ha-ras
gene could lead to skin tumors; doses for
chronic study were set at the NOEL or at a dose
atwhich toxicy was minimal.
Possible carcinogen; mutagen: doses for
chronic study were set at or near NOEL
observed in the subchronic study in both rats
and mice; low risk.
Unlikely carcinogen; nonmutagen: it is
unlikely that chronic skin irritation caused by a
nonmutagen will result in skin neoplasia;
chronic systemic effects in the rat kidney or
mouse liver could lead to a specific sex or
species neoplastic lesion, but the low doses
selected for the chronic study may minimize
that possiblity; low risk.
Possible carcinogen; nonmutagen: chronic
skin inflammation in both rats and mice unlikely
to result intumors; possible, but likely low
risk of liver tumors in MR or in mice; low risk.
Possible carcinogen; mutagen: accumulation
of hyalinelike droplets in the kidneythought
to be emodin or a metabolite, could cause focal
tubular lesions; very low risk for possible single-
sex/species target organ
(continued)
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Table 1. (Continued)
Chemical name Structural alertb Maximum dose tested
Route of administration Salb in chronic bioassayc Subchronic histopathologyd
CAS no (-/+ S9) Rats Mice Majortarget organs Comments and basis for prediction
Furfuryl alcohol
Inhalation
98-00-0
Isobutyraldehyde
Inhalation
78-84-2
Methyleugenol
Gavage
93-15-2
Oxymetholone
Gavage
434-07-1
Primaclone
Feed
125-33-7
Pyridine
Water
110-86-1
Sodium nitrite
Water
7632-00-0
Tetrahydrofuran
Inhalation
109-99-9
Vanadium pentoxide
Inhalation
1314-62-1
SA-
SA-
SA-
32 ppm 32 ppm
2000 ppm 2000 ppm
150 mg/kg 75 mg/kg
SA- 150 mg/kg MR;
100 mg/kg FR;
chronic study in rats only
SA- 0.25% 0.13%
SA-
SA-NA
SA-
SA-NA
Nasal cavity, both sex/species
Nasal cavity and thymus, both
sex/species; kidney, MM, FM
Stomach, liver in both
sex/species; kidney, adrenal
and salivary gland and
spleen in MR, FR; nasal
cavity in MM, FM
Mammary gland, adrenal gland,
kidney, MR, FR; ovary and
uterus, FR
Liver in both sex/species;
kidney, MR; adrenat gland
in MM
0.04% 0.10% MM Liver, MR, FR; kidney, MR; no
0.05% FM histopathologic lesions in mice
0.3% 0.3%
1800 ppm 1800 ppm
2 mg/m3 6 mg/m3
Forestomach and spleen
in both sex/species
Forestomach in both sex/
species; liver in MM, FM
Lung, both sex/species;
nose cavity and spleen
in MR, FR
Possible carcinogen; nonmutagen: chronic
inflammation of olfactory epithelium; high dose
in the subchronic study selected forthe
chronic study; an analog, furfural, was a
hepatocarcinogen in MR, MM, and FM. Question
ofwhether chronic inflammation and degenera-
tion ofthe nasal epithelium, especially in rats,
will lead to tumors; low risk.
Possible carcinogen; nonmutagen: acute
necrotizing inflammation ofthe nasal cavity and
lymphoid depletion in spleen and thymus in
both sex/species; hyperplasia ofthe renal
tubular epithelium in mice; considered to be
low risk.
Possible carcinogen; nonmutagen: possible
livertumors in MR, MM and FM; methyleugenol
shown to be a livertumor promoter in MM as
was 1-hydroxymethyleugenol, a metabolite of
ME; lowto moderate risk.
Possible carcinogen; nonmutagen: dialation
ofthe mammary gland and milk production in
both MR and FR; plasmic vacuolization of
adrenal cortical cells, and renal tubular
regeneration in MR and FR; ovarian follicular
atrophy in FR; moderate risk.
Possible carcinogen; mutagen: centrilobular
hypertrophy in the liver in both sex/species;
chronic kidney nephropathy in MR and cytoplasmic
alteration in MM adrenal gland.10-20% of
primaclone in the plasma is converted to pheno-
barbital, which is known to increase livertumor
incidence in mice and is a known livertumor
promoter in rats; lowto moderate risk.
Possible carcinogen; nonmutagen: hyaline
degeneration in MR kidney and centrilobular
degeneration in MR and FR liver; low riskfor
kidney tumors in MR and low riskfor liver
tumors in MR and FR.
Possible carcinogen; mutagen: focal hyperplasia
ofthe squamous epithelium atthe boundry of
the forestomach and glandular stomach;
extramedullary hematopoiesis ofthe spleen;
sodium nitrite can interact with amines and
amides to form nitroso compounds and
nitrosamines that are known animal carcino-
gens; next highest dose in subchronic study
selected as high dose in chronic study;
moderate risk.
Unlikelycarcinogen; nonmutagen: liver
cytomegaly was the major lesion in all mice
exposed to the highest subchronic dose
(5000 ppm) which was accompanied by
'narcosis"; the next lowerdose, 1800 ppm, was
selected as the chronic study high dose; if
chronic liver cytomegaly and/or necrosis is
minimal in mice, liver neoplasia is unlikely.
Possible carcinogen; nonmutagen: chronic
hyperplasia and inflammation ofthe bronchiolar
and alveolar eptithelium accompanied by
fibrosis; lowto moderate risk related to
spontaneous incidence of lung tumors in rats
and mice.
(continued)
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Table 1. (Continued)
Chemical name Structural alertb Maximum dose tested
Route of administration Salb in chronic bioassayc Subchronic histopathologyd
CAS no (-/+ S9) Rats Mice majortarget organs Comments and basis for prediction
Prediction calls abstained: results are known
Chloroprene SA+ 80 ppm 80 ppm Nasal cavity and liver, MR, FR; Possible carcinogen; nonmutagen:
Inhalation -/- forestomach, MM, FM a chlorine-unsaturated carbon bond could yield
126-99-8 an epoxide intermediate that could have
an activity similarto its structural analog,
1,3-butadiene, a potent carcinogen in mice; the
NOEL in the subchronic studywas 32 ppm in
both rats and mice.
Phenolphthaleine SA- 5.0% 1.2% No histopathologic lesions in Unlikely carcinogen; nonmutagen: no gross or
Feed -/- rats; bone marrowand spleen, histopathologic lesions observed in exposed rats;
77-09-8 MM, FM elevated incidence ofmicronucleated erythrocytes
in mice suggests a genotoxic metabolite ofthe
parent compound; cell depletion and necrosis
occurred in mouse bone marrow; phenophthalein
is unlikely to be a carcinogen unless chronic
high dose in mice causes neoplasia indirectly
via physiolological imbalance.
"All of the information used in these predictions, e.g., structures and subchronic toxicity, can be obtained through the NIEHS/NTP home pages: NIEHS:http://www.niehs.
nih.gov/exchange/ and NTP: http://ntp-server.niehs.nih.gov/. bStructural alert, SA (5): NA, criteria for determining structural alerts do not apply to inorganic compounds Sal.
Salmonellamutagenicity assay performed with and without S9-induced liver microsome preparations. cMaximum dose selected for chronic 2-year bioassay expressed as: %,
ppm, mg/kg or ppm/meter(m)3. dMajor target organs identified via histopatholog in the 13-week subchronic study: male rat (MR); female rat (FR); male mouse (MM); female
mouse (FM). NOEL = a "no effect level" was not reached in the subchronic study. "Nine chemicals that have undergone peer review priorto submission ofthis manuscript.
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